Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00529308 · ClinicalTrials.gov registry record · Phase 2
Transcranial Magnetic Stimulation (TMS) for Individuals With Tourette's Syndrome
A Phase 2 study of Tourette Syndrome, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT00529308: Completed Phase 2 study of Tourette Syndrome, sponsored by Yale University.
NCT00529308 is a Phase 2 study of Tourette Syndrome that has completed, run by Yale University. The registered enrollment target is 20 participants, below the 86-participant average among 33 other Tourette Syndrome trials with a reported enrollment target (77% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00529308, a Phase 2 study of Tourette Syndrome, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will evaluate the clinical efficacy of 1 Hz repetitive transcranial magnetic stimulation (rTMS) applied to the supplementary motor area (SMA) in Tourette's Syndrome (TS) patients who have not fully responded to conventional therapies. The investigators will collect TMS measures of motor cortex excitability to test whether rTMS restores normal levels of intracortical inhibition found to be deficient in TS. The investigators will administer neuropsychological tests to demonstrate that SMA targeted rTMS can be administered safely without significant impairments of cognitive or motor functioning. The investigators hypothesize that: 1. Compared to sham (placebo), active rTMS will improve symptoms of TS as assessed with the Yale Global Tic Severity Scale (Y-GTSS) and Clinical Global Impression (CGI). 2. Active (but not sham) rTMS will normalize levels of motor cortex excitability, as reflected by increased intracortical inhibition, motor threshold, and cortical silent period, and by decreased intracortical facilitation, relative to pre-treatment baseline.
Primary Outcome
Y-GTSS is a clinician-rated scale used to assess tic severity. Motor and phonic tics are rated separately from 0 to 5 on several scales including number, frequency, intensity, complexity, and interference. Thus Motor and Phonic Tic scores can range from 0 to 25; the combined Total Tic Score ranges from 0 to 50. There is also an Impairment score that rates the overall burden due to tics. The Impairment scale yields a single score from 0 to 50 with higher scores indicating higher levels of overall
Conditions Studied
Interventions
- DEVICE Transcranial Magnetic Stimulation (active)
- DEVICE Transcranial Magnetic Stimulation (sham)
Study Locations (2)
Connecticut
- Yale University School of Medicine - New Haven
New York
- New York State Psychiatric Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2007-07 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
What the finished NCT00529308 record still lists
NCT00529308 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 86-participant average among 33 other Tourette Syndrome trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Tourette Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Transcranial Magnetic Stimulation (active) is the first listed.
NCT00529308 reports a single indexed study location in Connecticut, New York.
Frequently Asked Questions
What is clinical trial NCT00529308 about?
NCT00529308 is a clinical study titled "Transcranial Magnetic Stimulation (TMS) for Individuals With Tourette's Syndrome". This study will evaluate the clinical efficacy of 1 Hz repetitive transcranial magnetic stimulation (rTMS) applied to the supplementary motor area (SMA) in Tourette's Syndrome (TS) patients who have not fully responded to conventional therapies. The investigators will collect TMS measures of motor c...
What is the current status of trial NCT00529308?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2007-07. Estimated completion is 2011-07.
What conditions does trial NCT00529308 study?
This clinical trial studies the following conditions: Tourette Syndrome.
What interventions are being tested in trial NCT00529308?
The interventions under investigation include: Transcranial Magnetic Stimulation (active) (DEVICE), Transcranial Magnetic Stimulation (sham) (DEVICE).
Who is sponsoring clinical trial NCT00529308?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00529308 being conducted?
This trial has 2 study locations across Connecticut, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tourette Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00529308's enrollment target sits among peer trials
20 27th of 33 higher than 5 of 33 other Tourette Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tourette Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Multimodal Profiling of Response to Pediatric Comprehensive Behavioral Intervention for Tics
RECRUITING · Phase 2
-
CBIT+TMS R33 Phase
RECRUITING · Phase 2
-
Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome
ACTIVE NOT RECRUITING · Phase 2
-
Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria
COMPLETED · Phase 2
-
Cognitive Behavior Therapy and Habit Reversal Training for the Treatment of Chronic Tic Disorders in Children
COMPLETED · Phase 2
-
Sensorimotor and Psychosocial Trajectories in Adolescents With Tic Disorder
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia